['liver cancer']
['idarubicin']

        Inclusion Criteria:

          -  - Histologically diagnosed HCC or HCC diagnosed according to the EASL criteria

          -  Measurable targets according to the mRECIST v1.1 criterion

          -  Preserved liver function (in case of Child-Pugh A or B7 cirrhosis)

          -  Tumour not subject to interventive care (liver transplant, surgical resection or
             percutaneous destruction)

          -  BCLC A/B without portal or extra-hepatic invasion

          -  No prior treatment by chemotherapy, radiotherapy or transarterial embolisation (with
             or without chemotherapy)

          -  Age ≥ 18 years

          -  WHO 0 or 1

          -  Laboratory test: platelets ≥ 50,000 mm3, N ≥ 1,000/mm3, creatininaemia ≤ 150 µmol/L,
             PT ≥ 50%

          -  No heart failure (isotope or ultrasound VEF > 50%)

        Exclusion Criteria:

          -  - Advanced tumour (vascular or extra-hepatic invasion including brain metastasis or
             diffuse HCC with liver invasion > 50%)

          -  History of other type of cancer except cancer known to be in remission for more than 5
             years (in this case, HCC histological proof is required), or basal-cell carcinoma or
             in situ cervix uteri cancer properly treated with curative treatment

          -  Advanced liver disease (Child B8, B9 and C, bilirubinaemia > 3 mg/dL, SGOT and SGPT >
             5 x ULN or 250 U/L)

          -  Previous treatment by idarubicin and/or doxorubicin

          -  Idarubicin contraindications (cardiopathy with myocardial failure, serious kidney or
             liver failure, yellow fever vaccine)

          -  Concurrent disease or uncontrolled severe clinical condition

          -  Uncontrolled severe infection

          -  Patient requiring long-term anticoagulant treatment

          -  Thrombosis of the portal vein or a 3-segment region or more

          -  Hepatofugal portal venous flow

          -  Presence of serious atheromatosis

          -  Presence of collateral vascular ways potentially affecting the normal regions during
             embolisation

          -  Presence of arthritis of the hepatic artery branches to be treated

          -  Presence of arterioportal or arterial subhepatic fistula that cannot be embolised by
             coils

          -  Pregnancy or breastfeeding

          -  Absence of effective contraception (for men and women of childbearing age)

          -  Patient who cannot be regularly monitored on account of psychological, social, family-
             or geography-related reasons

          -  Concomitant participation of a patient in another study
      